The role of glial cells and the complement system in retinal diseases and Alzheimer’s disease: common neural degeneration mechanisms

Experimental Brain Research

Volumn 232, Issue 11, 2014, Pages 3363-3377

  Harvey, Hannah ^a   Durant, Szonya ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Age related macular degeneration; Alzheimer s disease; Complement system; Glaucoma; Glia; Neurodegeneration

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT FACTOR H; MANNOSE BINDING LECTIN; NEUROTROPHIN; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; COMPLEMENT;

AGE RELATED MACULAR DEGENERATION; ALZHEIMER DISEASE; APOPTOSIS; ASTROCYTE; BRAIN DEVELOPMENT; BRUCH MEMBRANE; CELL INTERACTION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DEGENERATIVE DISEASE; DISEASE COURSE; GLAUCOMA; GLIA CELL; HIPPOCAMPUS; HUMAN; INTRACELLULAR SPACE; MICROGLIA; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHOTORECEPTOR CELL; PIGMENT EPITHELIUM; REVIEW; VISION; GLIA; METABOLISM; PATHOLOGY; PHYSIOLOGY; RETINA DISEASE;

ALZHEIMER DISEASE; COMPLEMENT SYSTEM PROTEINS; HUMANS; NEUROGLIA; RETINAL DISEASES;

EID: 84919654258     PISSN: 00144819     EISSN: 14321106     Source Type: Journal    
DOI: 10.1007/s00221-014-4078-7     Document Type: Review

References (142)

1. Abbas A, Lichtman A, Pillai S (2007) Cellular and molecular immunology. Elsevier, Philadelphia
2. Ambati J, Fowler B (2012) Mechanisms of age-related macular degeneration. Neuron 75:26–39. doi:10.1016/j.neuron.2012.06.018
3. Anderson D, Talaga K, Rivest A, Barron E, Hageman G, Johnson L (2004) Characterisation of beta amyloid assemblies in drusen: the deposits associated with ageing and age-related macular degeneration. Exp Eye Res 78:243–256. doi:10.1016/j.exer.2003.10.011
4. Anderson D, Radeke M, Gallo N, Chapin E, Johnson P, Curletti C, Hancox L, Hu J, Ebright J, Malek G, Hauser M, Rickman C, Bok D, Hageman G, Johnson L (2010) The pivotal role of the complement system in ageing and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29(2):95–112. doi:10.1016/j.preteyeres.2009.11.003
5. Atwood C, Martins R, Smith M, Perry G (2002) Senile plaque composition and posttranslational modification of amyloid-beta peptide and associated proteins. Peptides 23:1343–1350. doi:10.1016/S0196-9781(02)00070-0
6. Ballatore C, Lee V, Trojanowski J (2007) Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 8:663–672. doi:10.1038/nrn2194
7. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner R, Harlan J, Varlow E, Ebert U, Hillen H (2005) Globular amyloid beta-peptide 1-42 oligomer—a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem 10:1–14. doi:10.1111/j.1471-4159.2005.03407.x
8. Bayer A, Ferrari F, Erb C (2002) High occurrence rate of glaucoma among patients with Alzheimer’s disease. Eur Neurol 47:165–168. doi:10.1159/000047976
9. Behl C, Davis J, Lesley R, Schubert D (1994) Hydrogen peroxide mediates amyloid-β protein toxicity. Cell 77:817–827. doi:10.1016/0092-8674(94)90131-7
10. Bhutto I, McLeod S, Hasegawa T, Kim S, Merges C, Tong P, Lutty G (2006) Pigment epithelium-derived factor and vascular endothelial growth factor in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res 82(1):99–110. doi:10.1016/j.exer.2005.05.007
11. Binder C, Weismann D (2013) Patent No 20130011857. US Patent and Trademark Office, Washington, DC
12. Bora N, Kaliappan S, Jha P, Xu Q, Sivasankar B, Harris C, Morgan B, Bora P (2007) CD59: a complement regulatory protein, controls choroidal neovascularisation in a mouse model of wet-type age-related macular degeneration. J Immunol 178:1783–1790
13. Bora N, Jha P, Lyzogubov V, Kaliappan S, Liu J, Tytarenko R, Fraser D, Morgan B, Bora P (2010) Recombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in mice. J Biol Chem 285(44):33826–33833. doi:10.1074/jbc.M110.153130
14. Bosco A, Inman DM, Steele MR, Wu G, Soto I, Marsh-Armstrong N, Hubbard WC, Calkins DJ, Horner PJ, Vetter ML (2008) Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci 49(4):1437–1446. doi:10.1167/iovs.07-1337
15. Brantley M, Edelstein S, King J, Plotzke M, Apte R, Kymes S, Shiels A (2009) Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Eye 23:626–631. doi:10.1038/eye.2008.28
16. Bredt D, Snyder S (1994) Nitric oxide, a physiological messenger molecule. Ann Rev Biochem 63:175–195. doi:10.1146/annurev.bi.63.070194.001135
17. Buschini E, Piras A, Nuzzi R, Vercelli A (2011) Age related macular degeneration and drusen: neuroinflammation in the retina. Prog Neurobiol 95(1):14–25. doi:10.1016/j.pneurobio.2011.05.011
18. Caraci F, Battaglia G, Sortino M, Spampinato S, Molinaro G, Copani A, Nicoletti F, Bruno V (2012) Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic? Neurochem Int 61(4):559–565. doi:10.1016/j.neuint.2012.01.017
19. Cashman S, Ramo K, Kumar-Singh R (2011) A non membrane-targeted human soluble CD59 attenuates choroidal neovascularisation in a model of age related macular degeneration. PLoS One 6(4):e19078. doi:10.1371/journal.pone.0019078
20. Chandra J, Samali A, Orrenius S (2000) Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med 29:323–333. doi:10.1016/S0891-5849(00)00302-6
21. Chiu K, Chan T, Wu A, Leung I, So K, Chang R (2012) Neurodegeneration of the retina in mouse models of Alzheimer’s disease: what can we learn from the retina? Age (Dordr) 34(3):633–649. doi:10.1007/s11357-011-9260-2
22. Chrysostomou V, Reznaia F, Trounce I, Crowston J (2012) Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol 13:1–4. doi:10.1016/j.coph.2012.09.008
23. Cingle K, Kalski R, Bruner W, O’Brien C, Erhard P, Wyszynski R (1996) Age-related changes of glycosidases in human retinal pigment epithelium. Curr Eye Res 15(4):433–438. doi:10.3109/02713689608995834
24. Collard C, Väkevä A, Morrissey M, Agah A, Rollins S, Reenstra W, Buras J, Meri S, Stahl G (2000) Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol 156(5):1549–1556. doi:10.1016/S0002-9440(10)65026-2
25. Connor B, Young D, Yan Q, Faull R, Synek B, Dragunow M (1997) Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Mol Brain Res 499(1–2):71–81. doi:10.1016/S0169-328X(97)00125-3
26. Cordeiro M, Guo L, Luong V, Harding G, Wang W, Jones H, Moss S, Sillito A, Fitzke F (2004) Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc Natl Acad Sci USA 101:13352–13356. doi:10.1079/pnas.0405479101
27. Crabb J, Miyagi M, Gu X, Shadrach K, West K, Sakaguchi H, Kamei M, Hasan A, Yan L, Rayborn M, Salomon R, Hollyfield J (2002) Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci 99(23):14682–14687. doi:10.1073/pnas.222551899
28. Curcio C, Allen K (1990) Topography of ganglion cells in human retina. J Comp Neurol 300(1):5–25. doi:10.1002/cne.903000103
29. Dawson V, Dawson T (1996) Nitric oxide actions in neurochemistry. Neurochem Int 29(2):97–110. doi:10.1016/0197-0186(95)00149-2
30. Day A, Clark S, Bishop P (2011) Understanding the molecular basis of age-related macular degeneration and how the identification of new mechanisms may aid the development of novel therapies. Expert Rev Ophthalmol 6(2):123–128. doi:10.1586/EOP.11.10
31. de Castro J, Mullins R, Manea A, Hernandez J, Wallen T, Kuehn M (2013) Lipofuscin in human glaucomatous optic nerves. Exp Eye Res 111:61–66. doi:10.1016/j.exer.2013.03.019
32. Ding X, Patel M, Chan C (2009) Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 28(1):1–18. doi:10.1016/j.preteyeres.2008.10.001
33. Dowson J (1982) Neuronal lipofuscin accumulation in ageing and Alzheimer dementia: a pathogenic mechanism? Br J Psychiatry 140:142–148. doi:10.1192/byp.140.2.142
34. Dunaief J (2006) Iron induced oxidative damage as a potential factor in age-related macular degeneration: the Cogan lecture. Investig Ophthalmol Vis Sci 47:4660–4664. doi:10.1167/iovs.06-0568
35. Emerich D, Thanos C (2008) NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr Opin Mol Ther 10(5):506–515
36. Esparza T, Zhao H, Cirrito J, Cairns N, Bateman R, Holtzman D, Brody D (2013) Amyloid-beta oligomerization in Alzheimer dementia vs high pathology controls. Ann Neurol 73(1):104–119. doi:10.1002/ana.23748
37. Farina C, Aloisi F, Meinl E (2007) Astrocytes are active players in cerebral innate immunity. Trends Immunol 28(3):138–145. doi:10.1016/j.it.2007.01.005
38. Farkas R, Chowers I, Hackam A, Kageyama M, Nickells R, Otteson D, Duh E, Wang C, Valenta D, Gunatilaka T, Pease M, Quigley H, Zack D (2004) Increased expression of iron-regulating genes in monkey and human glaucoma. Investig Ophthalmol Vis Sci 45:1410–1417. doi:10.1167/iovs.03-0872
39. Fillit H, Ding W, Buee L, Kalman J, Altstiel L, Lawlor B, Wolf-Klein G (1991) Elevated circulating tumor necrosis factor levels in Alzheimer’s disease. Neurosci Lett 129(2):318–320. doi:10.1016/0304-3940(91)90490-K
40. Fischer B, Schmoll H, Platt D, Popa-Wagner A, Riederer P, Bauer J (1995) Complement C1q and C3 mRNA expression in the frontal cortex of Alzheimer’s patients. J Mol Med 73(9):465–471. doi:10.1007/BF00202265
41. Fishelson Z, Attali G, Mevorach D (2001) Complement and apoptosis. Mol Immunol 38(2–3):207–219. doi:10.1016/S0161-5890(01)00055-4
42. Gaipl U, Voll R, Sheriff A, Franz S, Kalden J, Hermann M (2005) Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev 4:189–194. doi:10.1016/j.autrev.2004.10.007
43. Garcia P, Youssef I, Utvij J, Florent-Béchard S, Barthélémy V, Malaplate-Armand C, Kriem B, Stenger C, Koziel V, Olivier J, Escanye M, Hanse M, Allouche A, Desbene C, Yen F, Bjerkvig R, Oster T, Niclou S, Pillot T (2010) Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer’s disease. J Neurosci 30(22):4182–4190. doi:10.1523/JNEUROSCI.4182-09.2010
44. Gasque P, Dean Y, McGreal E, VanBeck J, Morgan B (2000) Complement components of the innate immune system in health and disease in the CNS. Immunopharmacol 49:171–186. doi:10.1016/S0162-3109(00)80302-1
45. Gellrich M, Gellrich N (1996) Quantitative relations in the retinal ganglion cell layer of the rat: neurons, glia, and capillaries before and after optic nerve section. Graefe’s Arch Clin Exp Ophthalmol 234(5):315–323. doi:10.1007/BF00220707
46. Girouard H, Iadecola C (2006) Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 100:328–335. doi:10.1152/japplphysiol.00966.2005
47. Glabe C (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol Ageing 27:570–575. doi:10.1016/j.neurobiolaging.2005.04.017
48. Glovinsky Y, Quigley H, Pease M (1993) Foveal ganglion cell loss is size dependent in experimental glaucoma. Investig Ophthalmol Vis Sci 34(2):395–400
49. Goldberg J (2012) NT-501 CNTF implant for glaucoma: safety, neuroprotection, and neuroenhancement In: ClinicalTrialsgov [Internet] Bethesda (MD): Natl Library of Med (US). http://clinicaltrials.gov/show/NCT01408472
50. Gonzalez C (2012) Age macular degeneration-Alzheimer disease: relevance and interest of ophthalmologic exam in detection and follow-up of Alzheimer disease. Acta Ophthalmol 90(s249). doi:10.1111/j.1755-3768.2012.S087.x
51. Griffith L, Mathes M, Schmitz B (1995) Beta-amyloid precursor protein is modified with O-linked N-acetylglucosamine. J Neurosci Res 41(2):270–278. doi:10.1002/jnr.490410214
52. Guo L, Salt T, Luong V, Wood N, Cheung W, Maass A, Ferrari G, Russo-Marie F, Sillito A, Cheetham M, Moss S, Fitzke F, Cordeiro M (2007) Targeting amyloid-β in glaucoma treatment. Proc Natl Acad Sci 104:13444–13449. doi:10.1073/pnas.0703707104
53. Gupta N, Brown K, Milam A (2003) Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. Exp Eye Res 76(4):463–471. doi:10.1016/S0014-4835(02)00332-9
54. Hecker L, Edwards A, Ryu E, Tosakulwong N, Baratz K, Brown W, Issa P, Scholl H, Pollok-Kopp B, Schmid-Kubista K, Bailey K, Oppermann M (2010) Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum Mol Genet 19:209–215. doi:10.1093/hmg/ddp472
55. Holtkamp G, Kijlstra A, Peek R, de Vos A (2001) Retinal pigment epithelium-immune system interactions: cytokine production and cytokine-induced changes. Prog Retin Eye Res 20(1):29–48. doi:10.1016/S1350-9462(00)00017-3
56. Howell G, Zhu X, Van Eldik L, Watterson M, John S (2010) Assessing microglia/macrophages in DBA/2J glaucoma. Assoc Res Vis Ophthalmol 2098:A197
57. Jessen K (2004) Glial cells. Int J Biochem Cell Biol 36:1861–1867. doi:10.1016/j.biocell.2004.02.023
58. Jha P, Bora P, Bora N (2007) The complement system and ocular diseases. Mol Immunol 44(16):3901–3908. doi:10.1016/j.molimm.2007.06.145
59. Johnson L, Leitner W, Rivest A, Staples M, Radeke M, Anderson D (2002) The Alzheimer’s amyloid beta-peptide is deposited at sites of complement activation in pathologic deposits associated with ageing and age-related macular degeneration. Proc Natl Acad Sci USA 99:11830–11835. doi:10.1073/pnas.192203399
60. Kam J, Lenassi E, Jeffrey G (2010) Viewing ageing eyes: diverse sites of amyloid Beta accumulation in the ageing mouse retina and the up-regulation of macrophages. PLoS One 5:e13127. doi:10.1371/journal.pone.0013127
61. Khoury J, Luster A (2008) Mechanisms of microglia accumulation in Alzheimer’s disease: therapeutic implications. Trends Pharmacol Sci 29(12):626–632. doi:10.1016/j.tips.2008.08.004
62. Kim S, Kim J, Lee J, Cho S, Kang H, Kim K, Jin D (2013) Intravitreal human complement factor H in a rat model of laser-induced choroidal neovascularisation. Br J Ophthalmol 97(3):367–370. doi:10.1136/bjophthalmol-2012-302307
63. Kuehn M, Fingert J, Young K (2005) Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies. Ophthalmol Clin North Am 18:383–395. doi:10.1016/j.ohc.2005.04.002
64. Kumar S, Peña L, de Vellis J (1993) CNS glial cells express neurotrophin receptors whose levels are regulated by NGF. Mol Brain Res 17(1–2):163–168. doi:10.1016/0169-328X(93)90086-5
65. Kwon Y, Fingert J, Kuehn M, Alward W (2009) Primary open-angle glaucoma. N Engl J Med 360:1113–1124. doi:10.1056/NEJMra0804630
66. LaFerla F, Green K, Oddo S (2007) Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci 8:499–509. doi:10.1038/nrn2168
67. Lambert W, Agarwal R, Howe W, Clark A, Wordinger R (2001) Neurotrophin and neurotrophin receptor expression by cells of the human lamina cribrosa. Investig Ophthalmol Vis Sci 42(10):2315–2323
68. Lanzerein A, Jobst K, Thiel S, Jensenius J, Sim R, Perry H, Sim E (1998) Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimer’s disease. Clin Neurosci 9(7):1491–1495. doi:10.1097/00001756-199805110-00045
69. Laquis S, Chaudhary P, Sharma S (1998) The patterns of retinal ganglion cell death in hypertensive eyes. Brain Res 784(1–2):100–104. doi:10.1016/S0006-8993(97)01189-X
70. Law A, Gauthier S, Quirion R (2001) Say NO to Alzheimer’s disease: the putative links between nitric oxide and dementia of the Alzheimer’s type. Brain Res Rev 35(1):73–96. doi:10.1016/S0165-0173(00)00051-5
71. Le Fur I, Laumet G, Richard F, Fievet N, Berr C, Rouaud O, Delcourt C, Amouyel P, Lambert J (2010) Association study of the CFH Y402H polymorphism with Alzheimer’s disease. Neurobiol Ageing 31(1):165–166. doi:10.1016/j.neurobiolaging.2008.03.003
72. LeVine S (1997) Iron deposits in multiple sclerosis and Alzheimer’s disease brains. Brain Res 760:298–303. doi:10.1016/S0006-8993(97)00470-8
73. Liu B, Neufeld AH (2001) Nitric oxide synthase-2 in human optic nerve head astrocytes induced by elevated pressure in vitro. Arch Ophthalmol 119(2):240–245. doi:10-1001/pubs.Ophthalmol.-ISSN-0003-9950-119-2-els00027
74. Liu B, Chen H, Johns T, Neufeld A (2006) Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury. J Neurosci 26(28):7532–7540. doi:10.1523/JNEUROSCI.1004-06.2006
75. Lott I, Head E (2005) Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Ageing 26(3):383–389. doi:10.1016/j.neurobiolaging.2004.08.005
76. Lucin K, Wyss-Coray T (2009) Immune activation in brain ageing and neurodegeneration: too much or too little? Neuron 64(1):110–122. doi:10.1016/j.neuron.2009.08.039
77. Luibl V, Isas J, Kayed R, Glabe C, Langen R, Chen J (2006) Drusen deposits associated with ageing and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Investig 116(2):378–385. doi:10.1172/JCI25843
78. Lukiw W, Zhao Y, Cui J (2008) An NF-kB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 283(46):31315–31322
79. Lukiw W, Surjyadipta B, Dua P, Alexandrov P (2012) Common microRNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer’s disease (AD) and in age-related macular degeneration (AMD). Int J Biochem Mol Biol 3:105–116
80. Ma W, Coon S, Zhao L, Fariss R, Wong W (2013) A2E accumulation influences retinal microglial activation and complement regulation. Neurobiol Aging 34:943–960. doi:10.1016/j.neurobiolaging.2012.06.010
81. Mattson M, Goodman Y (1995) Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res 676:219–224. doi:10.1016/0006-8993(95)00148-J
82. McKinnon S (2003) Glaucoma: ocular Alzheimer’s disease? Front Biosci 8:1140–1156. doi:10.2741/1172
83. Mey J, Thanos S (1993) Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo. Brain Res 602(2):304–317. doi:10.1016/0006-8993(93)90695-J
84. Mold C, Morris C (2001) Complement activation by apoptotic endothelial cells following hypoxia/reoxygenation. Immunology 102:359–364. doi:10.1046/j.1365-2567.2001.01192.x
85. Morgan J, Caprioli J, Koseki Y (1999) Nitric oxide mediates excitotoxic and anoxic damage in rat retinal ganglion cells co-cultured with astroglia. Arch Ophthalmol 117(11):1524–1529. doi:10.1001/archopht.117.11.1524
86. Mousa S, Lorelli W, Campochiaro P (1999) Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. J Cell Biochem 74:135–143. doi:10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
87. Mullins R, Hagemann G (1999) Human ocular drusen possess novel core domains with a distinct carbohydrate composition. J Histochem Cytochem 47(12):1533–1539. doi:10.1177/002215549904701205
88. Nathanson J, McKee M (1995) Alterations of ocular nitric oxide synthase in human glaucoma. Invest Ophthalmol Vis Sci 36(9):1774–1784
89. Neufeld A (1999) Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Surv Ophthalmol 43(S1):S129–S135. doi:10.1016/S0039-6257(99)00010-7
90. Neufeld A, Sawada A, Becker B (1999) Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci USA 96:9944–9948. doi:10.1073/pnas.96.17.9944
91. Newman E, Reichenbach A (1996) The Müller cell: a functional element of the retina. Trends Neurosci 19(8):307–312. doi:10.1016/0166-2236(96)10040-0
92. Nischler C, Oberkofer H, Ortner C, Paikl D, Riha W, Lang N, Patsch W, Egger S (2011) Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol 89(4):344–349. doi:10.1111/j.1755-3768.2010.02080.x
93. Nunomura A, Castellani R, Zhu X, Moreira P, Perry G, Smith M (2006) Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 65(7):631–641. doi:10.1097/01.jnen.0000228136.58062.bf
94. Ohno-Mastui K (2011) Parallel findings in age-related macular degeneration and Alzheimer’s disease. Prog Retin Eye Res 30:217–238. doi:10.1016/j.preteyeres.2011.02.004
95. Pak K, Chan S, Mattson M (2003) Presenilin-1 mutation sensitizes oligodendrocytes to glutamate and amyloid toxicities and exacerbates which matter damage and memory impairment in mice. NeuroMol Med 3:53–64. doi:10.1385/NMM:3:1:53
96. Paulssen R, Moe B, Gonaas H, Orbo A (2008) Gene expression in endometrial cancer cells after short time high dose exposure to progesterone. Steroids 73(1):116–128. doi:10.1016/j.steroids.2007.09.010
97. Pease M, Zack D, Berlinicke C, Bloom K, Cone F, Wang Y, Klein R, Hauswirth W, Quiley H (2009) Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Investig Ophthalmol Vis Sci 50(5):2194–2200. doi:10.1167/iovs.08-3013
98. Posthumus R (1952) The use and the possibilities of progesterone in the treatment of glaucoma. Ophthalmol 124(1):17–25
99. Qu J, Wang D, Grosskreutz C (2010) Mechanisms of retinal ganglion cell injury and defense in glaucoma. Exp Eye Res 91:48–53. doi:10.1016/j.exer.2010.04.002
100. Quigley H, McKinnon S, Zack D, Pease M, Kerrigan-Baumrind L, Kerrigan D, Mitchell R (2000) Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Investig Ophthalmol Vis Sci 41(11):3460–3466
101. Roca-Santiago H, Lago-Bouza J, Millán-Calenti J, Gómez-Ulla-Irazazábal F (2006) Alzheimer’s disease and age-related macular degeneration. Arch Spanish Soc Ophthalmol 81:73–78. doi:10.4321/S0365-66912006000200006
102. Roh M, Zhang Y, Murakami Y, Thanos A, Lee S, Vavvas D, Benowitz L, Miller J (2012) Etancercept, a widely used inhibitor of tumor necrosis factor α prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One 7(7):e40065. doi:10.1371/journal.pone.0040065
103. Roth K, D’Sa C (2001) Apoptosis and brain development. Ment Retard Dev Disabil Res Rev 7(4):261–266. doi:10.1002/mrdd.1036
104. Rus H, Cudrici C, Niculescu F (2005) The role of the complement system in innate immunity. Immunol Res 33(2):103–112. doi:10.1385/IR:33:2:103
105. Saurenmann R, Levin A, Rose J, Parker S, Rabinovitch T, Tyrrell P, Feldman B, Laxer R, Schneider R, Silverman E (2006) Tumour necrosis factor α inhibitors in the treatment of childhood uveitis. Rheumatol 45(8):982–989. doi:10.1093/rheumatology/ke1030
106. Sávári M, Vágó I, Wéber C, Nagy J, Gál P, Mák M, Kósa J, Závodszky P, Pázmány T (2003) Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity. J Neuroimmunol 137(1–2):12–18. doi:10.1016/S0165-5728(03)00040-7
107. Schindowki K, Belarbi K, Buée L (2008) Neurotrophic factors in Alzheimer’s disease: role of axonal transport. Genes Brain Behav 7(S1):43–56. doi:10.1111/j.1601-183X.2007.00378.x
108. Selkoe D (2002) Alzheimer’s disease is a synaptic failure. Science 298:789–791. doi:10.1126/science.1074069
109. Shepard AR, Clark A, Klimko P, Wax M (2009) WIPO Patent No 2009061721. World Intellectual Property Organization, Geneva, Switzerland
110. Sihota R, Lakshmaiah N, Walia K, Sharma S, Pailoor J, Agarwal H (2001) The trabecular meshwork in acute and chronic angle closure glaucoma. Indian J Ophthalmol 49(4):255–259
111. Sivak J (2013) The ageing eye: common degenerative mechanisms between the Alzheimer’s brain and retinal disease. Investig Ophthalmol Vis Sci 54(1):871–880. doi:10.1167/iovs.12-10827
112. Skurla E, Rogers J, Sunderland T (1988) Direct assessment of activities of daily living in Alzheimer’s disease: a controlled study. J Am Geriatr Soc 36(2):97–103
113. Sohn J, Bora P, Jha P, Tezel T, Kaplan H, Bora N (2007) Complement, innate immunity and ocular disease. In: Niederkorn J, Kaplan H (eds) Immune response and the eye, vol 92. Karger, Basel, pp 105–114
114. Stasi K, Nagel D, Yang X, Wang R, Ren L, Podos S, Mittag T, Danias J (2006) Complement component 1Q upregulation in retina of murine, primate, and human glaucomatous eyes. Investig Ophthalmol Vis Sci 47(3):1024–1029. doi:10.1167/iovs.05-0830
115. Stevens B, Allen N, Vazquez L, Howell G, Christopherson K, Nouri N, Micheva K, Mehalow A, Huberman A, Stafford B, Sher A, Litke A, Lambris J, Smith S, John S, Barres B (2007) The classical complement cascade mediates CNS synapse elimination. Cell 131:1164–1178. doi:10.1016/j.cell.2007.10.036
116. Strasser A, O’Connor L, Dixit V (2000) Apoptosis signalling. Ann Rev Biochem 69:217–245. doi:10.1146/annurev.biochem.69.1.217
117. Strauss O (2005) The retinal pigment epithelium in visual function. Physiol Rev 85(3):845–881. doi:10.1007/s00347-008-1869-x
118. Streit W (2005) Microglia and neuroprotection: implications for Alzheimer’s disease. Brain Res Rev 48(2):234–239. doi:10.1016/j.brainresrev.2004.12.013
119. Tan B, Choi R, Chin T, Kaur C, Ling E (2012) Manipulation of microglial activity as a therapy for Alzheimer’s disease. Front Biosci 4:1402–1412. doi:10.2741/342
120. Taylor C, Senchyna M, Flanagan J, Joyce E, Cliché D, Boone A, Culp-Stewart S, Thompson J (2004) Role of eIF5A in TNF-α-mediated apoptosis of lamina cribrosa cells. Investig Ophthalmol Vis Sci 45(10):3568–3576. doi:10.1167/iovs.03-1367
121. Taylor S, Calder C, Albon J, Erichsen J, Boulton M, Morgan J (2011) Involvement of the CD200 receptor complex in microglia activation in experimental glaucoma. Exp Eye Res 92(5):338–343. doi:10.1016/j.exer.2011.01.012
122. Tezel G, Wax M (2000) Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in co-cultured retinal ganglion cells. J Neurosci 20(23):8693–8700
123. Tezel G, Li L, Patil R, Wax M (2001) TNF-α and TNF-α receptor-1 in the retina of normal and glaucomatous eyes. Investig Ophthalmol Vis Sci 42(8):1787–1794
124. Tezel G, Yang X, Luo C, Kain A, Powell D, Kuehn M, Kaplan H (2010) Oxidative stress and the regulation of complement activation in human glaucoma. Investig Ophthalmol Vis Sci 51(10):5071–5082. doi:10.1167/iovs.10-5289
125. Theodossiadis P, Markomichelakis N, Sfikakis P (2007) Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 27(4):399–413. doi:10.1097/MAJ.0b013e3180318fbc
126. Tichaczek-Goska D (2012) Deficiencies and excessive human complement system activation in disorders of multifarious etiology. Adv Clin Exp Med 21(1):105–114
127. Tobinick E (2007) Perispinal etanercept for treatment of Alzheimer’s disease. Curr Alzheimer Res 4(5):550–552. doi:10.2174/156720507783018217
128. Tobinick E, Gross H (2008) Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflamm 5(2). doi:10.1186/1742-2094-5-2
129. Van der Schaft T, Mooy C, de Bruijn W, de Jong P (1993) Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study. Br J Ophthalmol 77:657–661. doi:10.1136/bjo.77.10.657
130. Walker D, Kim S, McGeer P (1995) Complement and cytokine gene expression in cultured microglia derived from post-mortem human brains. J Neurosci Res 40:478–493. doi:10.1002/jnr.490400407
131. Walton H, Dodd P (2007) Glutamate-glutamine cycling in Alzheimer’s disease. Neurochem Int 50(7–8):1052–1066. doi:10.1016/j.neuint.2006.10.007
132. Wang L, Chiang H, Wu W, Liang B, Xie Z, Yao X, Ma W, Du S, Zhong Y (2012) Epidermal growth factor receptor is a preferred target for treating Amyloid-beta-induced memory loss. Proc Natl Acad Sci USA 109(41):16743–16748. doi:10.1073/pnas.1208011109
133. Webster S, Lue L-F, Brachova L, Tenner A, McGeer P, Terai K, Walker D, Bradt B, Cooper N, Rogers J (1997) Molecular and cellular characterization of the membrane attack complex C5b-9 in Alzheimer’s disease. Neurobiol Aging 18(4):415–421. doi:10.1016/S0197-4580(97)00042-0
134. Wittchen H, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen H-C (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655–679. doi:10.1016/j.euroneuro.2011.07.018
135. Wong W (2013) Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation. Front Cell Neurosci 7(22):1–13. doi:10.3389/fncel.2013.00022
136. Wordinger R, Fleenor D, Hellberg P, Pang I, Tovar T, Zode G, Fuller J, Clark A (2007) Effects of TGF-β2: BMP-4: and Gremlin in the trabecular meshwork: implications for glaucoma. Investig Ophthalmol Vis Sci 48(3):1191–1200. doi:10.1167/iovs.06-0296
137. Yang L, Li R, Meri S, Rogers J, Shen Y (2000) Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer’s disease. J Neurosci 20(20):7505–7509
138. Yin H, Chen L, Chen X, Liu X (2008) Soluble amyloid beta oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma. Med Hypotheses 71(1):77–80. doi:10.1016/j.mehy.2008.01.030
139. Yuan L, Neufeld A (2001) Activated microglia in the human glaucomatous optic nerve head. J Neurosci Res 64(5):523–532. doi:10.1002/jnr.1104
140. Yücel Y, Gupta N (2008) Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration. Prog Brain Res 173:465–478. doi:10.1016/S0079-6123(08)01132-1
141. Zetterberg M, Landgren S, Andersson M, Palmér M, Gustafson D, Skoog I, Minthon L, Thelle D, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zettenberg H (2008) Association of complement factor H Y402H gene polymorphism with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 147(6):720–726. doi:10.1002/ajmg.b.30668
142. Zhang J, Dawson V, Dawson T, Snyder S (1994) Nitric oxide activation of poly (ADP-ribose) synthetase in neurotoxicity. Science 263:687–689. doi:10.1126/science.8080500